Gilead Sciences, Inc. (GILD)
NASDAQ • Healthcare
August 21, 2026 at 17:40 UTC
About Gilead Sciences, Inc.
Gilead Sciences, Inc. discovers, develops, and commercializes medicines for critical health needs and trades on the NASDAQ as GILD. The biopharmaceutical company sits in healthcare, with FY2025 revenue of $29.4 billion, and its portfolio spans antiviral therapies, oncology and cell therapy products, and specialty cardiovascular treatments.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Gilead Sciences, Inc.'s Technical Indicators Summary
GILD exhibits a strong buy profile with broad momentum confirmation—a positive MACD, elevated CCI and strong momentum—while price trades above short, medium and 200-day averages and sits just above the VWAP. Trend strength is clear with ADX above 30 and OBV shows accumulation, indicating volume supports the advance. Volatility is moderate with ATR near $4, so moves appear measured rather than erratic. Technical takeaway: strong buy confirmed by trend strength, momentum and supportive volume and moving averages.
| Indicator | Value |
|---|---|
MFI | 69.64 |
RSI (14) | 68.17 |
Stochastic %K (14, 3, 3) | 85.69 |
CCI (20) | 163.07 |
WPR (14) | -8.42 |
Momentum (10) | 14.08 |
MACD Level (12, 26) | 3.66 |
Bollinger Bands | $125.15 - $147.16 |
ATR (14) | $4.06 (2.75%) |
ADX (14) | 30.60 |
OBV | 65,064,950 |
VWAP | $146.73 |
Classic Pivot Point | $144.48 |
Fibonacci Pivot Point | $144.48 |
Simple Moving Averages | $131.93 - $140.19(5 indicators) |
Exponential Moving Averages | $130.30 - $141.20(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
GILD punches higher, up 2.61% versus yesterday’s close of 143.44. A soft 1.52% sector rise adds a bit of lift to the backdrop. GILD chalks up gains after Q2 revenue growth and fresh CAR-T filing.
Trading Volume
Below 10d avg (5.2M)
1.9M
vs S&P 500 Today
Outperforming Market
+2.06%
52-Week Position
Upper range
79.3%
Updated: August 21, 2026 at 17:09 UTC
Quote Summary
GILD Headlines
Gilead lifts 2026 outlook after Q2 beat
August 4, 2026
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Biotech, Pharma Stocks Draw Fresh Valuation Focus
April 2, 2026
Gilead to buy Ouro, plan Galapagos tie-up
March 23, 2026